Improving the yield of circulating tumour cells facilitates molecular characterisation and recognition of discordant HER2 amplification in breast cancer.
BACKGROUND
Circulating tumour cells (CTCs) offer a non-invasive approach to obtain and characterise metastatic tumour cells, but their usefulness has been limited by low CTC yields from conventional isolation methods.


METHODS
To improve CTC yields and facilitate their molecular characterisation we compared the Food and Drug Administration-approved CellSearch Epithelial Kit (CEK) to a simplified CTC capture method, CellSearch Profile Kit (CPK), on paired blood samples from patients with metastatic breast (n=75) and lung (n=71) cancer. Molecular markers including Human Epidermal growth factor Receptor 2 (HER2) were evaluated on CTCs by fluorescence in situ hybridisation (FISH) and compared to patients' primary and metastatic cancer.


RESULTS
The median cell count from patients with breast cancer using the CPK was 117 vs 4 for CEK (P<0.0001). Lung cancer samples were similar; CPK: 145 cells vs CEK:4 cells (P<0.0001). Recovered CTCs were relatively pure (60-70%) and were evaluable by FISH and immunofluorescence. A total of 10 of 30 (33%) breast cancer patients with HER2-negative primary and metastatic tissue had HER2-amplified CTCs.


CONCLUSIONS
The CPK method provides a high yield of relatively pure CTCs, facilitating their molecular characterisation. Circulating tumour cells obtained using CPK technology demonstrate that significant discordance exists between HER2 amplification of a patient's CTCs and that of the primary and metastatic tumour.
Flores
L M
LM
Department of Medical Oncology, Dana-Farber Cancer Institute, Boston, MA, USA.
Kindelberger
D W
DW
Ligon
A H
AH
Capelletti
M
M
Fiorentino
M
M
Loda
M
M
Cibas
E S
ES
Jänne
P A
PA
Krop
I E
IE
D001943:Breast Neoplasms / Q000097:blood / Q000235:genetics*; D005260:Female; D005455:Fluorescent Antibody Technique; D005784:Gene Amplification; D018734:Genes, erbB-2 / Q000235:genetics*; D006801:Humans; D018189:Immunomagnetic Separation / Q000379:methods*; D017404:In Situ Hybridization, Fluorescence; D009360:Neoplastic Cells, Circulating
N Engl J Med. 2004 Aug 19;351(8):781-91
15317891
Clin Cancer Res. 2006 Nov 1;12(21):6403-9
17085652
Clin Cancer Res. 2008 Jun 15;14(12):3646-50
18559576
Clin Cancer Res. 2004 Oct 15;10(20):6897-904
15501967
Nature. 2007 Dec 20;450(7173):1235-9
18097410
Clin Cancer Res. 2007 Feb 1;13(3):920-8
17289886
Am J Pathol. 2000 Jan;156(1):57-63
10623654
Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4218-24
16857794
J Natl Cancer Inst. 2005 Aug 17;97(16):1185-94
16106023
Breast Cancer Res Treat. 2009 Dec;118(3):455-68
19115104
Clin Cancer Res. 2006 Mar 15;12(6):1715-20
16551854
Proc Natl Acad Sci U S A. 2004 Jun 22;101(25):9393-8
15194824
J Am Chem Soc. 2008 Jul 9;130(27):8633-41
18557614
N Engl J Med. 2008 Jul 24;359(4):366-77
18596266
Eur J Cancer. 2007 Dec;43(18):2645-50
17977713
Breast Cancer Res Treat. 2009 Dec;118(3):523-30
19597704
Cancer Treat Rev. 2009 Aug;35(5):463-74
19410375